WO1992016612A3 - Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component - Google Patents

Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component Download PDF

Info

Publication number
WO1992016612A3
WO1992016612A3 PCT/US1992/001915 US9201915W WO9216612A3 WO 1992016612 A3 WO1992016612 A3 WO 1992016612A3 US 9201915 W US9201915 W US 9201915W WO 9216612 A3 WO9216612 A3 WO 9216612A3
Authority
WO
WIPO (PCT)
Prior art keywords
padgem
cell
inhibitor
sialic acid
bearing
Prior art date
Application number
PCT/US1992/001915
Other languages
French (fr)
Other versions
WO1992016612A2 (en
Inventor
Bruce Furie
Barbara C Furie
Eric Larsen
Theresa Palabrica
Susan Sajer
Gary E Gilbert
Denisa D Wagner
Alessandro Celi
John Erban
Rosemary Gibson
Original Assignee
New England Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Inc filed Critical New England Medical Center Inc
Priority to JP4509676A priority Critical patent/JPH06508823A/en
Publication of WO1992016612A2 publication Critical patent/WO1992016612A2/en
Publication of WO1992016612A3 publication Critical patent/WO1992016612A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Abstract

The invention relates to a method of inhibiting (reducing or preventing) the interaction or adhesion of a PADGEM-bearing cell with a cell bearing a PADGEM ligand by contacting the PADGEM-bearing cell with an inhibitor comprising a 2,6-linked sialic acid component. By the method of the present invention, it is possible to inhibit the interaction of a PADGEM-bearing cell, such as a platelet or endothelial cell, with a cell bearing a PADGEM ligand, such as a white blood cell (leukocyte) by contacting the cell with an inhibitor comprising a 2,6-linked sialic acid residue. The invention further relates to inhibitors useful in the present method.
PCT/US1992/001915 1991-03-11 1992-03-09 Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component WO1992016612A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4509676A JPH06508823A (en) 1991-03-11 1992-03-09 Method for inhibiting PADGEM-mediated interactions using inhibitors containing 2,6 sialic acid components

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66745391A 1991-03-11 1991-03-11
US667,453 1991-03-11

Publications (2)

Publication Number Publication Date
WO1992016612A2 WO1992016612A2 (en) 1992-10-01
WO1992016612A3 true WO1992016612A3 (en) 1992-12-23

Family

ID=24678287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001915 WO1992016612A2 (en) 1991-03-11 1992-03-09 Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component

Country Status (4)

Country Link
EP (1) EP0575557A1 (en)
JP (1) JPH06508823A (en)
CA (1) CA2105997A1 (en)
WO (1) WO1992016612A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
DE69329333D1 (en) * 1992-03-20 2000-10-05 Cor Therapeutics Inc INHIBITION OF FACTOR X BY GLYCOSYLATION
WO1994007517A1 (en) 1992-10-02 1994-04-14 Alberta Research Council Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
DK0666914T3 (en) * 1992-10-23 2004-04-13 Inst Genetics Llc Hitherto unknown P-selectin ligand protein
CA2151142C (en) * 1992-11-16 2001-10-02 Richard D. Cummings Glycoprotein ligand for p-selectin and methods of use thereof
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
WO1995030001A2 (en) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein
EP0759781B1 (en) * 1994-06-03 2006-01-25 The CBR Institute for Biomedical Research, Inc. Compositions for treating and preventing atherosclerosis
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
US9609861B2 (en) 2011-05-17 2017-04-04 Velico Medical Inc. Platelet additive solution having a β-galactosidase inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006632A1 (en) * 1989-10-20 1991-05-16 New England Medical Center Hospitals, Inc. Inhibition of padgem-mediated cell binding

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006632A1 (en) * 1989-10-20 1991-05-16 New England Medical Center Hospitals, Inc. Inhibition of padgem-mediated cell binding

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, vol. 172, no. 3, 15 November 1990, Academic Press, Inc., L. CORRAL et al.: "Requirement for sialic acid on neutrophils in a GMP-140 (PADGEM) mediated adhesive interaction with activated platelets", pages 1349-1356, see the whole document, especially pages 1353-1355: "Discussion" (cited in the application) *
Cell, vol. 63, no. 3, 2 November 1990, Cell Press, E. LARSEN et al.: "PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate, LNF III (CD15)", pages 467-474, see the whole document (cited in the application) *
Proc. Soc. Exp. Biol. Med., vol. 198, no. 2, 1991, A. CELI et al.: "PADGEM: an adhesion receptor for leukocytes on stimulated platelets and endothelial cells", pages 703-709, see the whole document, especially page 705, column 2 *
Proceedings of the National Academy of Sciences of the USA, vol. 88, no. 14, 15 July 1991, M.J. POLLEY et al.: "CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-lewis X", pages 6224-6228, see the whole document *
The Journal of Cell Biology, vol. 112, no. 3, February 1991, The Rockefeller University Press, K.L. MOORE et al.: "GMP-140 binds to a glycoprotein receptor on human neutrophils: evidence for a lectin-like interaction", pages 491-499, see the whole document, especially pages 497-498: "Discussion" *
The Journal of Cell Biology, vol. 115, no. 2, October 1991, The Rockefeller University Press, Q. ZHOU et al.: "The selectin GMP-140 binds to sialylated, fucosylated lactosaminoglycans on both myeloid and nonmyeloid cells", pages 557-564, see the whole document *

Also Published As

Publication number Publication date
EP0575557A1 (en) 1993-12-29
CA2105997A1 (en) 1992-09-12
WO1992016612A2 (en) 1992-10-01
JPH06508823A (en) 1994-10-06

Similar Documents

Publication Publication Date Title
WO1992016612A3 (en) Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component
CA2067211A1 (en) Phospholipid- or lipid-linked glycosaminoglycan, process for producing the same and metastasis inhibitor
ZA9610100B (en) Neoacid corrosion inhibitors
AU7216594A (en) Machine dishwashing composition containing oxygen bleach and paraffin oil and benzotriazole compound silver tarnishing inhibitors
KR830004381A (en) Coating solution on metal surface
CA2138826A1 (en) Rinsing Compositions
MY113981A (en) Pharmaceutical composition containing a diclofenac salt and 2-hydroxypropyl-b-cyclodextrin
CA2138824A1 (en) Rinsing Compositions
WO1987001701A3 (en) Nitrogen-containing heterocyclic compounds
EP0353084A3 (en) Stabilized hydrogen peroxide compositions
NO992563D0 (en) Method of protecting metal surfaces from corrosion in liquid or gaseous media
GR3001441T3 (en) Pyrrolidinylamide ester derivative having anti-prolyl endopeptidase activity, its synthesis and use and a pharmaceutical composition containing it
AU8128691A (en) Hydrochloric acid donors as stabilizers for ACE inhibitor compositions
CA2042587A1 (en) Acrylic copolymer, process for the preparation of the same and use application of the same
DE69208375D1 (en) REMOVAL OF TETRAHYDROAZEPIN FROM AMINOCAPRONITRIL BY REACTION WITH REACTIVE METHYLENIC COMPOUNDS
EP0288254A3 (en) Polyoymethylene composition, and method for its manufacture
DE69412940D1 (en) METHOD AND COMPOSITION FOR REDUCING THE EFFECTS OF ENDOGENIC ALKALINE PHOSPHATASE
CA2159330A1 (en) Inhibition of leukocyte adhesion
CA1269383C (en) Herbicidal 2,6-bis-fluoromethyl-dihydropyridine-3,5- dicarboxylic acid esters
ATE137268T1 (en) METHOD FOR THE SPECIFIC DETERMINATION OF PANCREAS ALPHA-AMYLASE
AU5475680A (en) Infusion solution of amino acids + kinins
DE3164182D1 (en) Improvements relating to aminomethylenephosphonic acid solutions
CA2227607A1 (en) Penicillaminamide derivatives
WO1998002415A3 (en) Method for inhibiting corrosion and process for preparing 1-amidoalkylimidazoles
JPS5533499A (en) N2-arylsulfonyl-l-arginineamide and its pharmaceutically acceptable salt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 1992910663

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2105997

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992910663

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992910663

Country of ref document: EP